ARA 290
Cibinetide, an 11-amino-acid mimetic of the non-haematopoietic erythropoietin domain.
How it works
Binds the heterodimeric IRR-βcR tissue-protective receptor without engaging EpoR, providing anti-inflammatory and neuroprotective effects without erythropoiesis.
Reported benefits
- Improvement of small-fibre neuropathy in sarcoidosis trials
- Reduced neuropathic-pain scores
- Investigated for diabetic neuropathy
Dosage & administration
Trials used 4 mg subcutaneously daily.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
ARA 290 in sarcoidosis-associated small-fibre neuropathy
Molecular Medicine · 2014
Improved neuropathic symptoms and quality-of-life scores.
Safety & warnings
- Generally well tolerated
- Does not raise haematocrit (advantage over Epo)
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
RA10
Box of 10 · $216
Single vial · $432